Determining Individualized Cancer Therapy in Pancreatic Cancer

NCT05914987 | Recruiting

• 1 other identifier: PRO00048019
• Study Type: observational
• Target: 1,000
• Locations: 1 country
• Sites: 1

Brief Summary

This is a non-therapeutic exploratory observational precision oncology study designed to collect and analyze data that demonstrate the clinical efficacy and tolerability of personalized treatments based on molecular tumor profiling assessments (i.e., matched therapy) in adult pancreatic cancer patients. Patient medical records, obtained both retrospectively and prospectively, will be examined for results of molecular profiling obtained through standard of care testing to help understand how well molecular testing might predicts response to therapy. Patient demographic and outcome parameters to be evaluated include, but are not limited to, tumor response, time to treatment failure, patient survival, and toxicity.

Conditions

Pancreatic Neoplasms

Keywords

Mutation; Genomics; Targeted Therapy; Cancer; Pancreas

Outcome Measures

Primary Outcomes (1)

• Number of Subjects Receiving Targeted Therapy

  This measure is the number of study subject's whose treating physician prescribes and subsequently receives the therapeutic recommendation of the Molecular Tumor Board.

  5 years

Interventions

Targeted Therapy OTHER

Approved interventions based on the subject's genomic profile will be provided to investigators for consideration for anti-tumor therapy.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population will be selected from individuals seeking treatment for pancreatic cancer who have had next generation genomic sequencing of their tumors.

You may qualify if:

• Age ≥18 years.
• Pathologically confirmed pancreatic cancer.
• Ability to understand a written informed consent document and the willingness to sign it

You may not qualify if:

• Age \<18 years.
• Primary cancer diagnosis other than pancreatic cancer.

Sponsors & Collaborators

• Medical College of Wisconsin: lead

Study Sites (1)

Froedtert Hospital and the Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States

RECRUITING

MeSH Terms

Conditions

Pancreatic Neoplasms; Neoplasms

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Endocrine Gland Neoplasms; Digestive System Diseases; Pancreatic Diseases; Endocrine System Diseases

Study Officials

• Mandana Kamgar, MD

  Medical College of Wisconsin

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Cancer Center Clinical Trials Office

CONTACT

1-414-805-8900; cccto@mcw.edu

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor

Study Record Dates

• First Submitted: June 14, 2023
• First Posted: June 22, 2023
• Study Start: December 4, 2023
• Primary Completion (Estimated): August 1, 2028
• Study Completion (Estimated): August 1, 2033
• Last Updated: May 5, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)